Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Apr;61(4):337-42.
doi: 10.1136/thx.2005.045930. Epub 2006 Jan 31.

Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis

Affiliations
Randomized Controlled Trial

Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis

R Wilson et al. Thorax. 2006 Apr.

Abstract

Background: The MOSAIC study compared moxifloxacin with three standard antibiotic regimens in patients with Anthonisen type 1 acute exacerbations of chronic bronchitis (AECB). Further exploratory analyses were performed to identify prognostic factors of short and long term clinical outcomes and their value for clinical research.

Methods: Outpatients aged > or =45 years were screened between AECB episodes, randomised to treatment upon presenting with an AECB, assessed 7-10 days after study treatment, and followed monthly until a new AECB or for up to 9 months. Logistic regression assessed the predictive factors for clinical cure (return to pre-AECB status) and clinical success (cure or improvement), and a stepwise Cox regression model time to a composite event (failure of study treatment, new AECB, or further antibiotic treatment for AECB).

Results: In multivariate analyses, clinical cure was positively influenced by treatment with moxifloxacin (odds ratio (OR) 1.49; 95% CI 1.08 to 2.04) while cardiopulmonary disease (OR 0.59; 95% CI 0.38 to 0.90), forced expiratory volume in 1 second (FEV1) <50% predicted (OR 0.48; 95% CI 0.35 to 0.67), and > or =4 AECBs in the previous year (OR 0.68; 95% CI 0.48 to 0.97) predicted a poorer outcome. For clinical success, treatment with moxifloxacin had a positive influence (OR 1.57; 95% CI 1.03 to 2.41) while cardiopulmonary disease (OR 0.41; 95% CI 0.25 to 0.68) and use of acute bronchodilators (OR 0.50; 95% CI 0.30 to 0.84) predicted a poorer outcome. The occurrence of the composite event was influenced by antibiotic treatment (hazard ratio (HR) 0.82; 95% CI 0.68 to 0.98), age > or =65 years (HR 1.22; 95% CI 1.01 to 1.47), FEV1<50% predicted (HR 1.27; 95% CI 1.05 to 1.53), > or =4 AECBs in previous year (HR 1.63; 95% CI 1.34 to 1.99), and acute bronchodilator use (HR 1.48; 95% CI 1.17 to 1.87). For the composite event the beneficial effect of moxifloxacin was primarily seen in patients aged > or =65 years.

Conclusion: Despite selection of a homogeneous population of patients with chronic bronchitis, between group differences relating to antibiotic treatment could still be confounded by factors related to medical history, severity of disease, and use of concomitant medications. The design of future clinical trials should take these factors into account.

PubMed Disclaimer

Conflict of interest statement

Robert Wilson, Paul Jones and Tom Schaberg have acted as consultants and developed presentations for the sponsor for which they have received honoraria. Pierre Arvis, Isabelle Duprat‐Lomon and Pierre‐Philippe Sagnier are sponsor staff members.

Similar articles

Cited by

References

    1. Anthonisen N R, Manfreda J, Warren C P.et al Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987106196–204. - PubMed
    1. Kanner R E, Anthonisen N R, Connett J E.et al Lower respiratory illnesses promote FEV1 decline in current smokers but not ex‐smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001164358–364. - PubMed
    1. Donaldson G C, Seemungal T A R, Bhowmik A.et al Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 200257847–852. - PMC - PubMed
    1. Spencer S, Jones P W. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 200358589–593. - PMC - PubMed
    1. Patel I S, Seemungal T A, Wilks M.et al Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax 200257759–764. - PMC - PubMed

Publication types

MeSH terms